Literature DB >> 879870

Biostatistical basis of elective node dissection for malignant melanoma.

J G Fortner, J Woodruff, D Schottenfeld, B Maclean.   

Abstract

During the years 1954 through 1964, 259 individuals with primary malignant melanoma had an elective node dissection. Microscopic metastases were found in 15% of these patients. The presence of only a microscopic focus of involvement gave a 10-year cure rate of 67%; metastasis larger than a microscopic focus in a single node, 50%; and more than one node, 15%. One hundred forty-five individuals were treated by wide excision alone with 18% subsequently requiring a therapeutic lymphadenectomy with a ten-year cure of only 6%. A prospective study was then initiated which was concerned with efficacy of selection of patients for elective node dissection. Clark's level of invasion was determined for 258 patients treated since January 1972. The depth of invasion of the primary lesion was found to correlate directly with the absence of lymph node metastases, extent of nodal involvement, and rate of recurrence. It is concluded that the concept of elective node dissection is valid.

Entities:  

Mesh:

Year:  1977        PMID: 879870      PMCID: PMC1396205          DOI: 10.1097/00000658-197707000-00014

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  12 in total

1.  REGIONAL LYMPH NODE DISSECTION AND MALIGNANT MELANOMA. EFFECT OF SURVIVAL.

Authors:  W E PRICE; M K DUVAL
Journal:  Arch Surg       Date:  1963-11

2.  Regional lymphadenectomy and tumor immunity.

Authors:  W J Pendergrast; M S Soloway; G H Myers; J W Futrell
Journal:  Surg Gynecol Obstet       Date:  1976-03

3.  Method of analysis for evaluation of treatment in cancer of the oropharynx.

Authors:  E J MACDONALD
Journal:  Radiology       Date:  1962-05       Impact factor: 11.105

4.  Should lymphadenectomy be discarded? II. Malignant melanoma.

Authors:  R W Hiles
Journal:  J R Coll Surg Edinb       Date:  1973-11

5.  Studies concerning the regional lymph node in cancer. IV. Tumor inhibition by regional lymph node cells.

Authors:  B Fisher; E Saffer; E R Fisher
Journal:  Cancer       Date:  1974-03       Impact factor: 6.860

6.  Results of regional lymph node dissection for melanoma.

Authors:  S L Gumport; M N Harris
Journal:  Ann Surg       Date:  1974-01       Impact factor: 12.969

7.  The role of groin dissection in the management of melanoma of the lower extremity.

Authors:  J G McCarthy; C D Haagensen; F P Herter
Journal:  Ann Surg       Date:  1974-02       Impact factor: 12.969

8.  Should lymphadenectomy be discarded? I. Immunological considerations.

Authors:  M Baum
Journal:  J R Coll Surg Edinb       Date:  1973-11

9.  Selective regional lymphadenectomy for melanoma: a mathematical aid to clinical judgment.

Authors:  H C Polk; B S Linn
Journal:  Ann Surg       Date:  1971-09       Impact factor: 12.969

10.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

Authors:  W H Clark; L From; E A Bernardino; M C Mihm
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

View more
  17 in total

1.  A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 2.  Lymph node dissection for melanoma: where do we stand?

Authors:  Madalyn G Neuwirth; Edmund K Bartlett; Giorgos C Karakousis
Journal:  Melanoma Manag       Date:  2017-03-03

3.  Frequency of occult residual melanoma after excision of a clinically positive regional lymph node.

Authors:  M Kane; E McClay; R E Bellet
Journal:  Ann Surg       Date:  1987-01       Impact factor: 12.969

4.  Natural history of cutaneous malignant melanoma.

Authors:  H A Briele; T K Das Gupta
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

5.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

6.  Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis.

Authors:  D G Coit; A Rogatko; M F Brennan
Journal:  Ann Surg       Date:  1991-11       Impact factor: 12.969

7.  Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes.

Authors:  C Callery; A J Cochran; D J Roe; W Rees; S D Nathanson; J K Benedetti; R M Elashoff; D L Morton
Journal:  Ann Surg       Date:  1982-07       Impact factor: 12.969

8.  [Axillary recurrence after lymph node excision in malignant melanoma].

Authors:  L Kretschmer; C Lautenschläger; K P Preusser; H Fiedler; I Hetschko
Journal:  Langenbecks Arch Chir       Date:  1993

9.  Cutaneous melanoma of the breast.

Authors:  D F Roses; M N Harris; J S Stern; S L Gumport
Journal:  Ann Surg       Date:  1979-01       Impact factor: 12.969

10.  Importance of sentinel lymph node biopsy in patients with thin melanoma.

Authors:  Byron E Wright; Randall P Scheri; Xing Ye; Mark B Faries; Roderick R Turner; Richard Essner; Donald L Morton
Journal:  Arch Surg       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.